 Krystal Biotech, Inc. KRYS the Company, a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previously announced underwritten public offering of 2,275,000 shares of its common stock, at a public offering price of 55.00 per share. The Company granted the underwriters a 30-day option to purchase up to an additional 341,250 shares of its common stock. The gross proceeds to the Company from this offering are expected to be approximately 125.1 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. 